Modality
Multispecific
MOA
ALKi
Target
KIF18A
Pathway
JAK/STAT
MCC
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
Oct 2018
→ Aug 2031
Phase 1Current
NCT04049680
2,890 pts·MCC
2019-08→2030-05·Active
NCT05796936
2,200 pts·MCC
2018-10→2031-08·Not yet recruiting
5,090 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-05-064.1y awayPh2 Data· MCC
2031-08-135.4y awayPh2 Data· MCC
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2030-05-06 · 4.1y away
MCC
Ph2 Data
2031-08-13 · 5.4y away
MCC
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04049680 | Phase 1/2 | MCC | Active | 2890 | UPCR |
| NCT05796936 | Phase 1/2 | MCC | Not yet recr... | 2200 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |